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Background: Patients suffering from hypertrophic scars often describe esthetic, 
functional, and psychological impairments. While current guidelines for the treat-
ment of pathologic scarring recommend the use of onion extract containing gels and 
sheets, hard evidence for its efficacy remains scarce due to inconsistent data. Onion 
extract and allantoin containing occlusive overnight intensive patches (OIP) were in-
troduced as a recent option for noninvasive scar management. However, objective 
data demonstrating their efficacy are missing.
Aims: This study is the first to objectively evaluate the benefit and safety of an OIP 
for hypertrophic scars using a three-dimensional imaging device and a standardized 
scar scale.
Methods: Twelve patients with untreated, three to twelve months old hyper-
trophic scars received an OIP for 3 months. The assessment was performed using 
PRIMOS®pico, a three-dimensional imaging device and POSAS, a standardized scar 
questionnaire at baseline, one and 3 months after the last treatment.
Results: Objective evaluation at three months follow-up (FU) showed a significant 
decrease in scar height of 28.8% (baseline mean: 2.08 ± 0.68 mm, three months 
FU mean: 1.48 ± 0.52 mm) and a reduction in scar volume of 31.9% (baseline mean: 
454.33 ± 265.53 mm3, 3 months FU mean: 309.58 ± 224.28 mm3). Pain and pruritus 
subsided under treatment. There were no negative side effects.
Conclusion: Overnight intensive patches is a convenient, painless, safe, affordable 
and effective prevention and treatment option for hypertrophic scars. Treatment 
should be performed at least for 3 months for visible effects.
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1  | INTRODUC TION
Physiological wound healing is a complex cascade including three 
phases: inflammation, proliferation, and remodeling. In addition to a 
prolonged inflammatory phase, an increased liberation of transform-
ing growth factor isoenzymes (TGF-β1/β2) is held responsible for the 
excessive tissue formation in pathologic scarring.1,2 Scar formation is 
the result of an injury of the dermis followed by an imbalanced regen-
eration of the dermal tissue.3 Hypertrophic scars can develop six to 
eight weeks after an injury and form within the margins of the original 
wound.4 They can cause pain and pruritus and oftentimes have a seri-
ous psychosocial impact on affected patients.5 Over time, up to 70% 
of hypertrophic scars show signs of regression.4 However, prevention 
of scar formation by optimal wound care in early stages has proven to 
be crucial and easier than scar treatment.4,6
Onion extract (Extractum cepae), with its potent flavonoid com-
ponent quercetin, has been used for decades for scar management. 
It is known for its anti-inflammatory, anti-microbial, and anti-pro-
liferating effects by regulating TGF-ß1/ß2.7-9 Furthermore, studies 
have shown that quercetin reduces fibroblasts´ proliferation, thus 
induces the expression of matrix-metallo-proteinase-1, which leads 
to the remodeling of extracellular matrix (ECM) and ultimately re-
sults in an improved scar structure.10,11
Current German and international guidelines for the manage-
ment of pathological scarring include a rather weak recommenda-
tion for onion extract containing gels.4,12,13 Available data on the 
efficacy of extractum cepae for the prevention and treatment of 
hypertrophic scars are largely inconsistent and mostly based on sub-
jective means of evaluation.7-10,14,15 So far, the effectiveness of the 
novel application in form of an overnight intensive patch (OIP) has 
been examined in one multicenter clinical trial. However, evaluation 
was based predominantly on subjective parameters.16 OIP suggests 
superior results for hypertrophic scars through occlusion and con-
tinuous drug delivery overnight. The occlusive effect leads to an ac-
cumulation of moisture in the skin and facilitates the penetration of 
the active components for six to ten hours.16 Here, we examined OIP 
that contains onion extract and allantoin. Allantoin, a degradation 
product of uric acid, promotes epithelialization and skin elasticity 
with its keratolytic, moisturizing, and soothing effects.17
To evaluate this novel treatment regime and examine its viability 
for the treatment of hypertrophic scars, we employed a three-di-
mensional objective imaging device (Phase shift Rapid In-vivo 
Measurement of Skin (PRIMOS®pico)) and a standardized question-
naire (Patient and Observer Scar Assessment Scale (POSAS)).
2  | MATERIAL S AND METHODS
2.1 | Patients and study algorithm
A total of 12 patients with untreated hypertrophic scars, Fitzpatrick 
skin type I-III, consulting our outpatient clinic for pathologic scar-
ring (eight females, four males) aged 18-61 years (34.6 ± 13.4 years) 
were included in this prospective, single-center, open-label study 
after receiving approval by the Ethics Committee of the university 
hospital of the Ludwig-Maximilian-University in Munich. A negative 
control group was not allowed in this pilot study. Written informed 
consent was obtained from each patient before initiating the treat-
ment. Patients had to be of full age, healthy, with hypertrophic scars 
existing at least for three months but no longer than one year at 
the beginning of the study (mean age of hypertrophic scars was 
10 months). Scars were located on the forehead (n = 1), shoulder 
(n = 1), abdomen (n = 2), neck (n = 2), knee (n = 2), and arm (n = 4) and 
resulted from surgery (n = 9; fractures, cesarean section, thyroidec-
tomy) as well as from accidents (n = 3; bike, dog bite, burn).
Exclusion criteria were pregnancy and breastfeeding, malignant, 
infectious, or immunosuppressive diseases as well as a known type 
IV hypersensitivity to any OIP ingredient.
The patients were instructed to apply Contractubex® Overnight 
Intensive Patch (Merz Pharmaceuticals GmbH, Frankfurt am Main, 
Germany) every night (at least 6 hours, up to 10 hours), for 3 months 
onto the scar. The patch was cut to the appropriate scar size so that 
all margins were covered. At baseline (visit 1) as well as one month 
(visit 2) and three months after the treatment period (visit 3), data 
were obtained using PRIMOS®pico for objective evaluation and a 
standardized questionnaire (POSAS) for subjective evaluation by 
both the examiner and the patient. Adverse events related to the OIP 
application were recorded by the investigator at each visit. Subjects 
were instructed to strictly restrain from any other scar treatment 
during the study period (Figure 1).
2.2 | PRIMOS
PRIMOS®pico (Lite Device, GFMesstechnik GmbH) is a computer-
assisted surface measuring system which provides three-dimen-
sional, high-resolution images of skin. It is most commonly applied 
to measure wrinkles,18 but has been successfully used for evaluating 
volumes and dimensions of pathologic scarring throughout recent 
years.19-21 Using a handheld camera device, a pattern of parallel 
stripes is projected onto the skin. Irregularities of the skin surface 
result in a deflection of the stripe pattern which can then be used to 
calculate surface roughness parameters, such as the highest peak of 
the scars in mm (Smax). Based on height-coded images of scars, the 
volume was calculated in mm3. As the PRIMOS®pico allows examin-
ers to overlay previous captures via its build-in projector, it greatly 
facilitates follow-up documentation.
2.3 | POSAS
The Patient and Observer Scar Assessment Scale is the most estab-
lished questionnaire for evaluating pathologic scarring. The patient 
rates symptoms such as pain and itching of scars, as well as char-
acteristic features like color, stiffness, thickness, irregularity, and 
overall opinion compared to normal skin. The observer, a specialist 
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in scar prevention and scar therapy, evaluates vascularity of scars 
as well as pigmentation, thickness, relief, pliability, surface area and 
also states an overall opinion. Every category is scored from 1 to 10 
(least severe to most severe).22
2.4 | Data analysis
GraphPad Prism® Software (GraphPad Software Inc) was used 
to perform statistical analyses. D´Agostino and Pearson omnibus 
normality test was used to test for Gaussian distribution. Then, the 
repeated measures ANOVA was applied to calculate statistical sig-
nificance of our results, which were displayed as mean ± standard 
deviation. To compare the results of each visit in detail, we used 
Bonferroni's multiple comparison test. The significance level was 
set P-values of *P = <.05. The primary endpoint was defined as the 
change in the height of scars between the visits. Secondary end-
points were the change in volume of scars and the absolute change 
in the observer- and patient-evaluated POSAS scores between the 
visits.
F I G U R E  1   Study algorithm: Twelve 
patients with untreated hypertrophic 
scars were enrolled in the study. An onion 
extract and allantoin containing patch was 
applied every night for three months onto 
the scar. Data were collected at baseline 
(visit 1) and at one month and three 
months follow-up (visit 2 and visit 3) using 




- three to twelve months old scar




- infectious, malignant, immunosuppressive disease
- history of wound healing disorder
- type IV hypersensitivity to patch ingredient
collecting data at visit 1 (baseline)
PRIMOS 3D and POSAS questionnaire
patient with an untreated hypertrophic scar
3 months treatment period
applying Contratubex® Overnight Intensive Patch every night for 6 to 10 hours 
collecting data at visit 2 and 3 (one and three months follow-up)
PRIMOS 3D and POSAS questionnaire
F I G U R E  2   PRIMOS shows a clinical comparison of two cases in digital pictures (A) as well as in height-coded pictures (B) at visit 1 (left) 
and visit 3 (right), respectively
(A) (B)
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3  | RESULTS
3.1 | Safety and comfort
All patients completed the study and were very satisfied with the 
practical handling of the patches. Two females paused the applica-
tion for one night while reporting a slight erythema of the skin in the 
patch area. Besides that, no adverse events were observed.
3.2 | PRIMOS
PRIMOS®pico enabled a pre/postanalysis of scars showing the ef-
fect of the OIP through digital and color-coded pictures. (Figure 2) 
Objective evaluation showed that the highest peak of the hyper-
trophic scars (Smax) as well as the volume of the scars improved over 
the course of the study.
Smax, the primary endpoint, presented with a mean score of 
2.08 ± 0.68 mm at visit 1. After treatment, we found a significant 
reduction down to 1.72 ± 0.54 mm at visit 2 and 1.48 ± 0.52 mm at 
visit 3 (P < .05). Hence, this translated into a relative improvement 
in the scar's height of 17.3% when comparing visit 1 and visit 2 and 
28.8% when comparing visit 1 and visit 3.
On average, the scar's volume at visit 1 was 454.33 ± 265.53 
mm3. Measurements showed a reduction down to 393.17 ± 234,84 
mm3 at visit 2 and 309.58 ± 224.28 mm3 at visit 3, thus, resulting in 
a relative improvement of 13.5% between visit 1 and visit 2, and of 
31.9% between visit 1 and visit 3 (P > .05) (Figure 3).
3.3 | POSAS
Significant improvements were seen in the observer-evaluated 
POSAS scales comparing visit 1 to visit 3 in categories of vascularity, 
pigmentation, thickness, relief, pliability, and surface area comparing 
hypertrophic scars to normal skin. We observed an absolute reduc-
tion from 3.2 ± 1.1 points at visit 1 to 1.7 ± 1.0 points at visit 3 in 
the overall opinion score. Evaluation of the patient-evaluated POSAS 
also revealed significant improvements in scar characteristics be-
tween visit 1 and visit 3 regarding pain, itching, color difference, 
stiffness, thickness, and irregularity of scars. The overall opinion 
score dropped from 7.8 ± 1.6 points at visit 1 to 4.7 ± 2.5 points at 
visit 3 (Figures 4, 5).
4  | DISCUSSION
This pilot study confirmed the efficacy and safety of an OIP con-
taining onion extract and allantoin for the treatment of hypertrophic 
scars. Compared to previous clinical trials, this study provides ob-
jective data on this subject, even though investigating a small case 
number.7,14,16,23
The study met its primary objective by showing a significant 
decrease in scar height after only three months of treatment. 
Importantly, we found a long-lasting positive effect of OIP appli-
cation with further improvements of investigated parameters after 
visit 2 and 3. It remains to be seen whether these improvements 
were caused by the treatment or through natural regression of the 
scars, as hypertrophic scars frequently show significant involution 
without treatment before they have matured. Future studies should 
include an untreated control group or split-phase design to further 
elucidate this issue.
PRIMOS measurements of scar volume—the secondary end-
point—showed improvements between post-treatment visits, how-
ever, without significant differences. Possibly, the variance in scar 
lengths could have contributed to volume deviation. Use of B-mode 
ultrasound or optical coherence tomography could provide more 
precise information in this regard in future studies, especially when 
considering, that PRIMOS only measures scar volume above the skin 
surface. Subcutaneous scar tissue and its development unfortu-
nately cannot be assessed using PRIMOS technology.
Confirmation of the efficacy was further supported by com-
parison of POSAS scores. Significant differences were detected in 
all categories while comparing the scars to normal skin before and 
three months after the treatment period.
The noninvasive and painfree application of the OIP led to high 
patient satisfaction with this form of treatment. It was well toler-
ated throughout the study and proved cost-effective. Application 
was uncomplicated, and the patches could be worn overnight, while 
other gel-based solutions have to be renewed throughout the day. 
F I G U R E  3   Absolute height (left) 
and absolute volume of hypertrophic 
scars (right) using PRIMOS for 
objective analysis. (n = 12, P** = .008, 
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Even in difficult anatomic locations like the knee or the head, patch 
adherence was maintained without complications.
Our results provide clinical data for the effective treatment of 
hypertrophic scars with occlusive OIP containing onion extract and 
allantoin. The efficacy of both these active ingredients has previ-
ously been evaluated by different study groups.7-11 Based on the 
hypothesis that an imbalance of MMP activity and ECM synthesis 
leads to excessive accumulation of matrix and thus causes formation 
of hypertrophic scars, Cho et al were able to demonstrate that onion 
extract increased the expression of MMP-1, leading to a decrease 
in scar formation in an in vitro and in vivo setting.11 For allantoin, 
Araújo et al showed that topical application of allantoin ameliorated 
scar tissue formation and fastened the reestablishment of vital, 
healthy skin in rodents.17
The greatest limitation of this study is the small number of cases. 
Furthermore, by using a ready-to-use medical device in contrast to 
the vehicle or the active ingredients alone, this study could not draw 
any conclusions about the contribution of each individual component 
with regard to the overall efficacy. In an experimental rat model, 
Sahin et al could demonstrate that Contratubex® gel with its active 
ingredients onion extract and allantoin was more effective than allan-
toin monotherapy in the treatment of scars.24 Moreover, it would be 
interesting to see whether a continued OIP application would result 
in further improvement of scars. Not only the treatment period but 
also the follow-up time should be prolonged in further studies.
So far, the study by Prager et al is the only one examining the 
effectiveness of an onion extract and allantoin containing OIP in the 
treatment of hypertrophic scars. 125 patients were treated in an 
intra-individual randomized, controlled design.16 The study showed 
that OIP promotes healing of postdermatologic surgery scars. There 
were no safety concerns, and the comfort of the application was 
emphasized. Our results deliver objective data to support these 
findings.
In accordance with many previous studies on onion extract and 
allantoin gel application, our current study demonstrates a safe and 
viable use of the novel OIP technique in the treatment of hypertro-
phic scars.7,25 Undesirable effects were rare, bearing in mind that 
the ingredients of the patch could possibly lead to an allergic con-
tact dermatitis. Patients with known allergies should be monitored 
closely.
F I G U R E  4   Observer scar assessment scale rating characteristics of hypertrophic scars comparing visit 1 to visit 3, respectively. (n = 12, 
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F I G U R E  5   Patient scar assessment 
scale rating characteristics of 
hypertrophic scars comparing visit 1 to 
visit 3, respectively. (n = 12, P*** = <.0003, 
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5  | CONCLUSION
The beneficial effect of occlusive OIP containing onion extract and 
allantoin should be considered for prophylaxis and treatment of hy-
pertrophic scars. Patch application should be performed for at least 
three months for visible effects. Especially, due to the increasing 
number of pharmaceutical and cosmetic skin products, objective 
evaluation on their efficacy is required more than ever.
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